Literature DB >> 14982753

Both fasting glucose production and disappearance are abnormal in people with "mild" and "severe" type 2 diabetes.

Rita Basu1, W Frederick Schwenk, Robert A Rizza.   

Abstract

To determine whether regulation of fasting endogenous glucose production (EGP) and glucose disappearance (R(d)) are both abnormal in people with type 2 diabetes, EGP and R(d) were measured in 7 "severe" (SD), 9 "mild" (MD), and 12 nondiabetic (ND) subjects (12.7 +/- 0.6 vs. 8.1 +/- 0.4 vs. 5.1 +/- 0.4 mmol/l) after an overnight fast and during a hyperglycemic pancreatic clamp. Fasting insulin was higher in both the SD and MD than ND subjects, whereas fasting glucagon only was increased (P < 0.05) in SD. Fasting EGP, glycogenolysis, gluconeogenesis, and R(d) all were increased (P < 0.05) in SD but did not differ in MD or ND. On the other hand, when glucose ( approximately 11 mmol/l), insulin ( approximately 72 pmol/l), and glucagon ( approximately 140 pg/ml) concentrations were raised to values similar to those observed in the severe diabetic subjects, EGP was higher (P < 0.001) and R(d) lower (P < 0.01) in both SD and MD than in ND. The higher EGP in the SD and MD than ND during the clamp was the result of increased (P < 0.05) rates of glycogenolysis (4.2 +/- 1.7 vs. 3.5 +/- 1.0 vs. 0.0 +/- 0.8 micromol.kg(-1).min(-1)), since gluconeogenesis did not differ among groups. We conclude that neither glucose production nor disappearance is appropriate for the prevailing glucose and insulin concentrations in people with mild or severe diabetes. Both increased rates of gluconeogenesis (likely because of higher glucagon concentrations) and lack of suppression of glycogenolysis contribute to excessive glucose production in type 2 diabetics.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14982753     DOI: 10.1152/ajpendo.00549.2003

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  31 in total

1.  Diurnal rhythm in endogenous glucose production is a major contributor to fasting hyperglycaemia in type 2 diabetes. Suprachiasmatic deficit or limit cycle behaviour?

Authors:  J Radziuk; S Pye
Journal:  Diabetologia       Date:  2006-05-16       Impact factor: 10.122

2.  Prediabetes linked to excess glucagon in transgenic mice with pancreatic active AKT1.

Authors:  Toya M Albury-Warren; Veethika Pandey; Lina P Spinel; Michal M Masternak; Deborah A Altomare
Journal:  J Endocrinol       Date:  2015-10-20       Impact factor: 4.286

3.  Long non-coding RNA H19 inhibition promotes hyperglycemia in mice by upregulating hepatic FoxO1 levels and promoting gluconeogenesis.

Authors:  Neha Goyal; Shweta Tiwary; Devesh Kesharwani; Malabika Datta
Journal:  J Mol Med (Berl)       Date:  2018-11-21       Impact factor: 4.599

4.  Paradigm Shifts in Nocturnal Glucose Control in Type 2 Diabetes.

Authors:  Ananda Basu; Nisha Joshi; John Miles; Rickey E Carter; Robert A Rizza; Rita Basu
Journal:  J Clin Endocrinol Metab       Date:  2018-10-01       Impact factor: 5.958

5.  A comprehensive compartmental model of blood glucose regulation for healthy and type 2 diabetic subjects.

Authors:  O Vahidi; K E Kwok; R B Gopaluni; F K Knop
Journal:  Med Biol Eng Comput       Date:  2015-10-22       Impact factor: 2.602

6.  Pathogenesis of fasting and postprandial hyperglycemia in type 2 diabetes: implications for therapy.

Authors:  Robert A Rizza
Journal:  Diabetes       Date:  2010-08-12       Impact factor: 9.461

7.  Pathogenesis of prediabetes: role of the liver in isolated fasting hyperglycemia and combined fasting and postprandial hyperglycemia.

Authors:  Rita Basu; Cristina Barosa; John Jones; Simmi Dube; Rickey Carter; Ananda Basu; Robert A Rizza
Journal:  J Clin Endocrinol Metab       Date:  2013-01-23       Impact factor: 5.958

8.  Hepatic glucose production pathways after three days of a high-fat diet.

Authors:  Eunsook S Jin; Sara A Beddow; Craig R Malloy; Varman T Samuel
Journal:  Metabolism       Date:  2012-09-12       Impact factor: 8.694

9.  Effects of 11β-hydroxysteroid dehydrogenase-1 inhibition on hepatic glycogenolysis and gluconeogenesis.

Authors:  J J Winnick; C J Ramnanan; V Saraswathi; J Roop; M Scott; P Jacobson; P Jung; R Basu; A D Cherrington; D S Edgerton
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-02-12       Impact factor: 4.310

10.  Effects of type 2 diabetes on insulin secretion, insulin action, glucose effectiveness, and postprandial glucose metabolism.

Authors:  Ananda Basu; Chiara Dalla Man; Rita Basu; Gianna Toffolo; Claudio Cobelli; Robert A Rizza
Journal:  Diabetes Care       Date:  2009-02-05       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.